tbuckley/cabot-search huggingface dataset:
The End Justifies the Means—A Call for Nuance in the Increasing Nationwide Adoption of Stereoelectroencephalography Over Subdural Electrode Monitoring in the Surgical Evaluation of Intractable Epilepsy
Authors: Chima O. Oluigbo, William D. Gaillard, Mohamad Z. Koubeissi
Journal: JAMA Neurology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Renal Response in Patients with Relapsed Refractory Multiple Myeloma: Interim Data of a Large, Observational, Prospective Study
Authors: Javier De La Rubia, Queralt Salas, Enrique Morales, Esther González, Maria Soledad Durán, Fernando Escalante, Mercedes Gironella, Tomás José González-López, Rafael Duro, Manuel Pérez, Paz Ribas, Elena Cabezudo, Rafael Lluch, Ignacio Español, Valentin Cabañas, Ricardo García-Muñoz, Jose Antonio Márquez, Marta Duran, Javier Soriano, Antoni García
Journal: Blood (2016)
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial
Authors: Eva Giné, Fátima de la Cruz, Ana Jiménez Ubieto, Javier López Jimenez, Alejandro Martín García-Sancho, M. José Terol, Eva González Barca, María Casanova, Adolfo de la Fuente, Ana Marín-Niebla, Ana Muntañola, Tomás José González-López, Marta Aymerich, Xavier Setoain, Montserrat Cortés-Romera, Amanda Rotger, Sonia Rodríguez, Alejandro Medina Herrera, Ramón García Sanz, Ferran Nadeu, Silvia Beà, Elías Campo, Armando López-Guillermo
Journal: Journal of Clinical Oncology (2022)

The need for an individualized management of indolent clinical forms in mantle cell lymphoma (MCL) is increasingly recognized. We hypothesized that a tailored treatment with ibrutinib in combination with rituximab (IR) could obtain significant responses in these patients.This is a multicenter single-arm, open-label, phase II study with a two-stage design conducted in 12 Spanish GELTAMO sites (ClinicalTrials.gov identifier: NCT02682641). Previously untreated MCL patients with indolent clinical forms defined by the following criteria were eligible: no disease-related symptoms, nonblastoid variants, Ki-67 < 30%, and largest tumor diameter ≤ 3 cm. Both leukemic non-nodal and nodal subtypes were recruited. Patients received ibrutinib 560 mg once daily and a total of eight doses of rituximab 375 mg/m2. Ibrutinib could be discontinued after 2 years in the case of sustained undetectable minimal residual disease (MRD). The primary end point was the complete response (CR) rate achieved after 12 cycles according to Lugano criteria.Fifty patients with MCL (male 66%; median age 65 years) were enrolled. After 12 cycles of treatment, 42 (84%; 95% CI, 74 to 94) patients had an overall response, including 40 (80%; 95% CI, 69 to 91) with CR. Moreover, undetectable MRD in peripheral blood was achieved in 87% (95% CI, 77 to 97) of cases. At 2 years, 24 of 35 evaluable patients (69%) could discontinue ibrutinib because of undetectable MRD. Four patients had disease progression; three were non-nodal MCL and carried high genomic complexity and TP53 mutations at enrollment. No unexpected toxicity was seen except one patient with severe aplastic anemia.Frontline IR combination achieves a high rate of CRs and undetectable MRD in indolent clinical forms of MCL. Discontinuation seems appropriate in cases with undetectable MRD, except for TP53-mutated cases.
Flow cytometric characterization of platelet function and platelet-leukocyte interactions under treatment with clopidogrel in the course of coronary intervention Christoph Altmann, Dirk Welge, Michael Haude, Judith Vonnahme, Heinrich Wieneke, Lothar Volbracht, Raimund Erbel. University Hospital Essen, Essen, Germany
Journal: Journal of the American College of Cardiology (2001)
A nationwide school fruit and vegetable policy and childhood and adolescent overweight: A quasi-natural experimental study
Authors: Bente Øvrebø, Tonje H. Stea, Ingunn H. Bergh, Elling Bere, Pål Surén, Per Magnus, Petur B. Juliusson, Andrew K. Wills
Journal: PLoS Medicine (2022)

Background School free fruit and vegetable (FFV) policies are used to promote healthy dietary habits and tackle obesity; however, our understanding of their effects on weight outcomes is limited. We assess the effect of a nationwide FFV policy on childhood and adolescent weight status and explore heterogeneity by sex and socioeconomic position. Methods and findings This study used a quasi-natural experimental design. Between 2007 and 2014, Norwegian combined schools (grades 1–10, age 6 to 16 years) were obligated to provide FFVs while elementary schools (grades 1–7) were not. We used 4 nationwide studies ( n = 11,215 children) from the Norwegian Growth Cohort with longitudinal or cross-sectional anthropometric data up to age 8.5 and 13 years to capture variation in FFV exposure. Outcomes were body mass index standard deviation score (BMI SDS ), overweight and obesity (OW/OB), waist circumference (WC), and weight to height ratio (WtHR) at age 8.5 years, and BMI SDS and OW/OB at age 13 years. Analyses included longitudinal models of the pre- and post-exposure trajectories to estimate the policy effect. The participation rate in each cohort was &gt;80%, and in most analyses &lt;4% were excluded due to missing data. Estimates were adjusted for region, population density, and parental education. In pooled models additionally adjusted for pre-exposure BMI SDS , there was little evidence of any benefit or unintended consequence from 1–2.5 years of exposure to the FFV policy on BMI SDS , OW/OB, WC, or WtHR in either sex. For example, boys exposed to the FFV policy had a 0.05 higher BMI SDS (95% CI: −0.04, 0.14), a 1.20-fold higher odds of OW/OB (95% CI: 0.86, 1.66) and a 0.3 cm bigger WC (95% CI: −0.3, 0.8); while exposed girls had a 0.04 higher BMI SDS (95% CI: −0.04, 0.13), a 1.03 fold higher odds of OW/OB (95% CI: 0.75, 1.39), and a 0-cm difference in WC (95% CI: −0.6, 0.6). There was evidence of heterogeneity in the policy effect estimates at 8.5 years across cohorts and socioeconomic position; however, these results were inconsistent with other comparisons. Analysis at age 13 years, after 4 years of policy exposure, also showed little evidence of an effect on BMI SDS or OW/OB. The main limitations of this study are the potential for residual confounding and exposure misclassification, despite efforts to minimize their impact on conclusions. Conclusions In this study we observed little evidence that the Norwegian nationwide FFV policy had any notable beneficial effect or unintended consequence on weight status among Norwegian children and adolescents.
Conversion of initially unresectable hepatocellular carcinoma (HCC) with triple-combination therapy (lenvatinib, anti-PD-1 antibodies, and transarterial therapy): A retrospective analysis.
Authors: Tianqiang Song, Mengran Lang, Wei Lu, Ti Zhang, Huikai Li, Qiang Wu, Yunlong Cui, Wei Zhang, Qiang Li, Fenglin Zang, Wenge Xing, Shaohua Ren, Leijuan Gan
Journal: Journal of Clinical Oncology (2022)

413 Background: Combination therapy with tyrosine kinase inhibitors and anti-PD-1 antibodies can allow selected patients with initially unresectable HCC to convert to surgical resection. We evaluated conversion therapy with a triple combination of lenvatinib (LEN), anti-PD-1 antibodies and transarterial therapy. Methods: We retrospectively searched medical records from 117 consecutive patients with unresectable/advanced HCC who received triple combination therapy between Dec 2018 and Oct 2020 at Tianjin Medical University Cancer Institute &amp; Hospital. Eligible patients were required to have potentially resectable HCC, defined as meeting ≥1 of the following criteria: 1) estimated future liver remnant after radical (R0) resection of &lt; 40% or &lt; 30% in patients with/without cirrhosis, respectively; 2) R0 resection technically difficult to complete; 3) Child-Pugh score ≥7, ECOG performance status ≥1; 4) tumor thrombus in the main portal vein or inferior vena cava; 5) resectable extrahepatic metastases. The primary endpoint was the proportion of patients who underwent a successful resection (conversion rate). Secondary endpoints included objective response rate (ORR), disease control rate (DCR), 6-month disease-free survival (DFS) and safety. Results: Of 37 patients included in the analysis, all received LEN and anti-PD-1 antibodies with transarterial chemoembolization (TACE, n = 22), hepatic arterial infusion chemotherapy (HAIC, n = 9) or both (n = 6). The conversion rate was 40.5% (15) and the ORR and DCR were 67.7% and 86.5% by RECIST v1.1 and 75.7% and 86.5% by mRECIST, respectively. The median conversion time was 4 months (range: 2-15). After a median postoperative follow-up time of 10 months (95% CI, 6.42-13.58), the 6-month DFS rate was 93%. Overall, 89.2% of patients had ≥1 treatment emergent adverse event (TEAE) and 29.7% experienced a Grade 3/4 TEAE, the most common was hypertension (18.9%, n = 7). Conclusions: A triple combination of LEN, anti-PD-1 antibodies and transarterial therapy was well tolerated and effective at converting potentially resectable HCC to resectable disease. These findings warrant confirmation by future prospective studies.
Abstract 17124: Aortic Valve Calcification as a Predictor of Post-TAVR Pacemaker Dependence
Authors: Esseim Sharma, Antony F Chu, Brian D McCauley
Journal: Circulation (2018)

Introduction: Atrioventricular block requiring permanent pacemaker (PPM) implantation is a common complication of TAVR. Our group has previously reported that a significant number of patients receiving PPM immediately post-TAVR do not require right ventricular (RV) pacing at 30 days. The mechanism of AV block during TAVR is not fully understood, but is thought to partly be due to the mechanical stress of TAVR deployment and resultant tissue edema, resulting in possible injury to the nearby compact AV node. Aortic valve calcification (AVC) may worsen this condition and has been associated with an increased risk for post-TAVR PPM implantation. We performed a retrospective analysis to determine if AVC is predictive for long-term RV pacing in post-TAVR pacemaker patients at 30 days. Methods: Prospectively collected data of 262 consecutive patients who underwent TAVR with placement of a balloon-expandable valve at Rhode Island Hospital from March 2012 to October 2016 were analyzed. AVC data were derived from contrast-enhanced computed tomography and characterized by leaflet sector and region. Results: A total of 25 patients (11.1%) required post-TAVR PPM implantation. Seventeen patients did not require RV pacing at 30 days. Nine of these 17 patients had no RV pacing requirement within 10 days. Non-coronary leaflet (NCL) calcium volume was significantly higher in patients who were pacemaker dependent at 30 days ( p =0.01) and a calcium volume of &gt;200mm 3 in the NCL was significantly associated with pacemaker dependence at 30 days (OR 51.9, 2.3-1170.2, p = 0.01). Pre-existing RBBB (OR 105.4, 4.52-2458.5, p=0.0002), bifascicular block (OR 12.50, 1.60-97.65, p=0.02), intra-procedural complete heart block (OR 12.83, 1.26-130.52, p =0.03), and QRS duration &gt;120ms (OR 70.43, 3.23-1535.22, p=0.0002) were also significantly associated with pacemaker dependence at 30 days. Conclusions: Quantification of AVC by non-coronary leaflet calcium volume was found to be a novel predictor for RV pacing dependence at 30 days. The association of NCL calcification and pacemaker dependence may be related to the proximity of the conduction bundle to the non-coronary leaflet. Further studies are necessary to improve risk prediction for long-term RV pacing requirements following TAVR.
Infant deaths from respiratory syncytial virus in Lusaka, Zambia from the ZPRIME study: a 3-year, systematic, post-mortem surveillance project
Authors: Christopher J Gill, Lawrence Mwananyanda, William B MacLeod, Geoffrey Kwenda, Rachel Pieciak, Zachariah Mupila, Caitriona Murphy, Chilufya Chikoti, Leah Forman, Flora Berklein, Rotem Lapidot, Charles Chimoga, Benard Ngoma, Anna Larson, James Lungu, Ruth Nakazwe, Diana Nzara, Lillian Pemba, Baron Yankonde, Angel Chirwa, Magda Mwale, Donald M Thea
Journal: The Lancet Global Health (2022)
AWSnet: An auto-weighted supervision attention network for myocardial scar and edema segmentation in multi-sequence cardiac magnetic resonance images
Authors: Kai-Ni Wang, Xin Yang, Juzheng Miao, Lei Li, Jing Yao, Ping Zhou, Wufeng Xue, Guang-Quan Zhou, Xiahai Zhuang, Dong Ni
Journal: Medical Image Analysis (2022)
Action and Interaction of Hormones and 3-Methycholanthrene on the Ventral Prostate Gland of the Rat &lt;italic&gt;In Vitro&lt;/italic&gt;. I. Testosterone and Methylcholanthrene
Authors: Ilse Lasnitzki
Journal: JNCI Journal of the National Cancer Institute (1965)

The effect of testosterone and 3-methylcholanthrene, applied singly and combined, on organ cultures of the ventral prostate gland of the rat, in natural and semidefined medium, was studied. In medium without added hormone the glandular epithelium regressed. The regression was more severe in the natural medium and was accompanied by a marked increase of stroma. Testosterone inhibited the stromal growth and partially maintained the epithelium in the natural medium; in the semidefined medium it fully maintained the epithelium and preserved secretory activity. After more prolonged treatment testosterone induced mild epithelial hyperplasia. 3-Methylcholanthrene caused rapid and extensive hyperplasia of the alveolar epithelium. After transfer to control medium the hyperplasia persisted. Simultaneous administration of testosterone and 3-methylcholan-threne and transfer of explants pretreated with 3-methylcholanthrene to medium containing testosterone resulted in a drastic inhibition of the hyperplasia caused by the carcinogen. It is suggested that the interaction of the two substances may take place at the lysosomal level.
Plastics Used Successfully in Ophthalmology
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Outcomes based on treatment setting in refractory acute myeloid leukemia and other high-grade myeloid malignancies
Authors: Noam E. Kopmar, Megan Othus, Kelda M. Gardner, Carole Shaw, Anna B. Halpern, Bart L. Scott, Paul C. Hendrie, Roland B. Walter, Pamela S. Becker, Elihu H. Estey, Mary-Elizabeth M. Percival
Journal: Leukemia (2022)
Defining the Impact of Family History on Detection of High-grade Prostate Cancer in a Large Multi-institutional Cohort
Authors: Matthew B. Clements, Emily A. Vertosick, Lourdes Guerrios-Rivera, Amanda M. De Hoedt, Javier Hernandez, Michael A. Liss, Robin J. Leach, Stephen J. Freedland, Alexander Haese, Francesco Montorsi, Stephen A. Boorjian, Cedric Poyet, Donna P. Ankerst, Andrew J. Vickers
Journal: European Urology (2021)
Electrophysiological heterogeneity in large populations of rabbit ventricular cardiomyocytes
Authors: Quentin Lachaud, Muhamad Hifzhudin Noor Aziz, Francis L Burton, Niall Macquaide, Rachel C Myles, Radostin D Simitev, Godfrey L Smith
Journal: Cardiovascular Research (2022)

Cardiac electrophysiological heterogeneity includes: (i) regional differences in action potential (AP) waveform, (ii) AP waveform differences in cells isolated from a single region, (iii) variability of the contribution of individual ion currents in cells with similar AP durations (APDs). The aim of this study is to assess intra-regional AP waveform differences, to quantify the contribution of specific ion channels to the APD via drug responses and to generate a population of mathematical models to investigate the mechanisms underlying heterogeneity in rabbit ventricular cells.APD in ∼50 isolated cells from subregions of the LV free wall of rabbit hearts were measured using a voltage-sensitive dye. When stimulated at 2 Hz, average APD90 value in cells from the basal epicardial region was 254 ± 25 ms (mean ± standard deviation) in 17 hearts with a mean interquartile range (IQR) of 53 ± 17 ms. Endo-epicardial and apical-basal APD90 differences accounted for ∼10% of the IQR value. Highly variable changes in APD occurred after IK(r) or ICa(L) block that included a sub-population of cells (HR) with an exaggerated (hyper) response to IK(r) inhibition. A set of 4471 AP models matching the experimental APD90 distribution was generated from a larger population of models created by random variation of the maximum conductances (Gmax) of 8 key ion channels/exchangers/pumps. This set reproduced the pattern of cell-specific responses to ICa(L) and IK(r) block, including the HR sub-population. The models exhibited a wide range of Gmax values with constrained relationships linking ICa(L) with IK(r), ICl, INCX, and INaK.Modelling the measured range of inter-cell APDs required a larger range of key Gmax values indicating that ventricular tissue has considerable inter-cell variation in channel/pump/exchanger activity. AP morphology is retained by relationships linking specific ionic conductances. These interrelationships are necessary for stable repolarization despite large inter-cell variation of individual conductances and this explains the variable sensitivity to ion channel block.
Amer J Obstetrics &amp;amp; Gynecology, St. Louis
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice
Authors: Anna S. Lok
Journal: Hepatology (2011)

We appreciate Dr. Ridruejo and colleagues' interest in our article. We would like to clarify that the high rate of virological breakthrough we observed in our practice does not mean that nucleos(t)ide analog treatment is ineffective in suppressing hepatitis B viral (HBV) replication. Table 2 showed that 71% of patients (53% HBeAg-positive) had undetectable HBV DNA at 1 year, similar to what had been reported in clinical trials. The point that we wish to make is that during long-term treatment, transient virological breakthroughs are common and some of these episodes of breakthrough are related to medication nonadherence rather than antiviral drug resistance, particularly when antiviral drugs with high genetic barrier to resistance are used. Confirmation of virological breakthrough and/or testing for drug resistance mutation would avoid unnecessary changes to the treatment regimen. Because of the transient nature of some of these breakthroughs, the frequency with which they are observed depends on the frequency of HBV DNA monitoring. In our practice, HBV DNA is monitored every 3 months throughout the course of treatment. The rates of breakthrough would likely be lower if our patients were monitored every 6 months or less often. Anna S. Lok XX*, * University of Michigan Health System, Ann Arbor, MI.
Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
Authors: M. Socinski, V. Velcheti, T. Mekhail, Y.K. Chae, T.A. Leal, J.E. Dowell, M.L. Tsai, C.S. Dakhil, P. Stella, V. Shen, S. Hu, S.M. Paul, D.S. Shames, E. Schleifman, D.A. Fabrizio, M. Nowicki, C. Yun, S. Phan, E.S. Kim
Journal: Annals of Oncology (2019)
Endothelial function and plasma endothelin-1 levels following administration of estradiol valerate and cyproterone acetate in menopausal women at risk for CAD Giuseppe M. C. Rosano, Filippo Leonardo, Giuseppe Mercuro, Sandra Zoncu, Massimo Fini. San Raffaele - Roma - TOSINVEST SANITA', Roma, Italy, University of Cagliari, Cagliari, Italy
Journal: Journal of the American College of Cardiology (2001)